SCHEMBL6163522

SCHEMBL6163522

Cn1nc(CO)cc1-c1cccc(Br)c1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ALDH1A1 P00352 2/20 0.39
PTGS2 P35354 1/20 0.39
CA1 P00915 3/20 0.38
CA2 P00918 3/20 0.38
CA9 Q16790 3/20 0.38
GAA P10253 2/20 0.38
MAPT P10636 2/20 0.38
TP53 P04637 1/20 0.38
KDM4E B2RXH2 1/20 0.38
GABRG2 P18507 5/20 0.37
GABRB3 P28472 5/20 0.37
GABRA5 P31644 5/20 0.37
GABRA3 P34903 5/20 0.37
GABRA1 P14867 4/20 0.37
NR1H4 Q96RI1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1779503 0.82 PTGS2 (0.52) PTGS2CA1CA2CA9MAPT
SCHEMBL5396378 0.77 NR1H4 (0.41) PTGS2CA1CA2CA9NR1H4
SCHEMBL6165772 0.75 GABRG2 (0.46) ALDH1A1CA1CA2CA9GABRG2
SCHEMBL2203114 0.75 RPA1 (0.51) MEN1KMT2AALDH1A1MAPT
SCHEMBL5396375 0.74 FYN (0.39) PTGS2CA1CA2CA9NR1H4
SCHEMBL4504419 0.74 PLA2G10 (0.55) ALDH1A1CA1CA2CA9KDM4E
SCHEMBL5026993 0.73 PTGS2 (0.51) PTGS2CA1CA2CA9TP53
SCHEMBL22769348 0.73 NR1H4 (0.45) PTGS2CA1CA2CA9NR1H4
SCHEMBL21807369 0.73 CSNK1D (0.46) PTGS2CA1CA2CA9NR1H4
SCHEMBL20805341 0.72 NR1H4 (0.44) KMT2AALDH1A1PTGS2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379511-B1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II HOFFMANN LA ROCHE (CH) 2005-07-20 EP disclosed
EP-1379511-A1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II F. HOFFMANN-LA ROCHE AG (CH) 2004-01-14 EP disclosed
US-6544985-B2 For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits HOFFMAN-LA ROCHE INC. 2003-04-08 US disclosed
US-20020193367-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) 2002-12-19 US disclosed
WO-2002083652-A1 DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II F. HOFFMANN-LA ROCHE AG (CH) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193367-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives CYP1B1, GRIN2B, BDKRB1 KCNH2 463/4885MEN1 1887/4885KMT2A 1244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.